1. acute febrile infection (body acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or had symptoms suggestive of covid-19 within the last 28 days or had case contact within the last 10 days before the inclusion visit. 2. virologically documented (pcr or serology) history of covid 19. 3. immunosuppressive drugs such as corticosteroids at a dosage \> 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies. 4. treated with immunoglobulin or other blood product within 3 months prior to inclusion or scheduled for administration of immunoglobulin or blood product before the end of the study. 5. known hiv, hcv or hbv infection. 6. any condition, such as cancer, that may reduce the immune response. 7. use of experimental ig, experimental monoclonal antibodies or convalescent serum is not allowed during the study. 8. history of severe adverse reactions after vaccine administration including anaphylactic reaction and associated symptoms such as rash, difficulty breathing, angioedema and abdominal pain, or a history of an allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine during the first vaccine injection. 9. participant having been vaccinated against bcg in the previous year. 10. having received a vaccination within 2 weeks prior to the 2nd booster dose or scheduled to receive a licensed vaccine 2 weeks after the 2nd booster dose. 11. any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy or receipt of anticoagulants. 12. participation in other research involving humans (french classification jardé 1 or jardé 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial. 13. subject under legal protection (e.g. guardianship, tutorship).

1. acute febrile infection (body acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or had symptoms suggestive of covid-19 within the last 28 days or had case contact within the last 10 days before the inclusion visit. 2. virologically documented (pcr or serology) history of covid 19. 3. immunosuppressive drugs such as corticosteroids at a dosage \> 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies. 4. treated with immunoglobulin or other blood product within 3 months prior to inclusion or scheduled for administration of immunoglobulin or blood product before the end of the study. 5. known hiv, hcv or hbv infection. 6. any condition, such as cancer, that may reduce the immune response. 7. use of experimental ig, experimental monoclonal antibodies or convalescent serum is not allowed during the study. 8. history of severe adverse reactions after vaccine administration including anaphylactic reaction and associated symptoms such as rash, difficulty breathing, angioedema and abdominal pain, or a history of an allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine during the first vaccine injection. 9. participant having been vaccinated against bcg in the previous year. 10. having received a vaccination within 2 weeks prior to the 2nd booster dose or scheduled to receive a licensed vaccine 2 weeks after the 2nd booster dose. 11. any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy or receipt of anticoagulants. 12. participation in other research involving humans (french classification jardé 1 or jardé 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial. 13. subject under legal protection (e.g. guardianship, tutorship).

acute febrile infection (body acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or had symptoms suggestive of covid-19 within the last 28 days or had case contact within the last 10 days before the inclusion visit. virologically documented (pcr or serology) history of covid 19. immunosuppressive drugs such as corticosteroids at a dosage > 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies. treated with immunoglobulin or other blood product within 3 months prior to inclusion or scheduled for administration of immunoglobulin or blood product before the end of the study. known hiv, hcv or hbv infection. any condition, such as cancer, that may reduce the immune response. use of experimental ig, experimental monoclonal antibodies or convalescent serum is not allowed during the study. history of severe adverse reactions after vaccine administration including anaphylactic reaction and associated symptoms such as rash, difficulty breathing, angioedema and abdominal pain, or a history of an allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine during the first vaccine injection. participant having been vaccinated against bcg in the previous year. having received a vaccination within 2 weeks prior to the 2nd booster dose or scheduled to receive a licensed vaccine 2 weeks after the 2nd booster dose. any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy or receipt of anticoagulants. participation in other research involving humans (french classification jardé 1 or jardé 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial. subject under legal protection (e.g. guardianship, tutorship).

acute febrile infection (body acute febrile infection (body temperature ≥ 38.0°c) within the previous 72 hours and/or had symptoms suggestive of covid-19 within the last 28 days or had case contact within the last 10 days before the inclusion visit. virologically documented (pcr or serology) history of covid 19. immunosuppressive drugs such as corticosteroids at a dosage > 10 mg prednisone equivalent/day (excluding topical preparations and inhalers) within 3 months prior to inclusion or within 6 months for chemotherapies. treated with immunoglobulin or other blood product within 3 months prior to inclusion or scheduled for administration of immunoglobulin or blood product before the end of the study. known hiv, hcv or hbv infection. any condition, such as cancer, that may reduce the immune response. use of experimental ig, experimental monoclonal antibodies or convalescent serum is not allowed during the study. history of severe adverse reactions after vaccine administration including anaphylactic reaction and associated symptoms such as rash, difficulty breathing, angioedema and abdominal pain, or a history of an allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine during the first vaccine injection. participant having been vaccinated against bcg in the previous year. having received a vaccination within 2 weeks prior to the 2nd booster dose or scheduled to receive a licensed vaccine 2 weeks after the 2nd booster dose. any bleeding disorder considered as a contraindication to an intramuscular injection, previous phlebotomy or receipt of anticoagulants. participation in other research involving humans (french classification jardé 1 or jardé 2) within 4 weeks prior to the inclusion visit, or participation in any other vaccine trial. subject under legal protection (e.g. guardianship, tutorship).